Physician profile
Peter Diaz
NPI 1760594808
$789.79
in general payments reported to CMS, 2019-2025
11 companies · $21.35 in 2025
The $21.35 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $495 · 2022: $260 · 2024: $13.59 · 2025: $21.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $314.67 | 2021-2022 | |
| Abbvie INC. | $121.53 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $120.28 | 2021 | |
| Amgen INC. | $85.68 | 2021-2022 | |
| Antares Pharma, INC. | $29.30 | 2022 | |
| Medtronic, INC. | $28.45 | 2022-2024 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $27.62 | 2021 | |
| Boston Scientific Corporation | $21.35 | 2025 | Varithena Administration Pack |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.05 | 2022 | |
| Amarin Pharma, INC. | $13.45 | 2022 | |
| Merck Sharp & Dohme LLC | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.